Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.32 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17198902 | 0.71 | HSP90AA1 (0.38) | CA2CHKAHSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL24525054 | 0.71 | SMARCA2 (0.35) | CA2CHKASMARCA2SMARCA4 | |
| SCHEMBL25183576 | 0.69 | CDK8 (0.37) | HSP90AB1ALDH1A1KDM4ESMARCA2SMARCA4 | |
| SCHEMBL26151613 | 0.68 | GABRA2 (0.33) | HSP90AA1HSP90AB1SMARCA2SMARCA4 | |
| SCHEMBL17480644 | 0.67 | CYP3A4 (0.38) | HSP90AA1HSP90AB1SMARCA2SMARCA4 | |
| SCHEMBL9135390 | 0.67 | HSP90AA1 (0.31) | HSP90AA1HSP90AB1SMARCA2SMARCA4 | |
| SCHEMBL26970954 | 0.67 | LOX (0.32) | SMARCA2SMARCA4LOXL2LOX | |
| SCHEMBL24958741 | 0.67 | SMARCA2 (0.33) | SMARCA2SMARCA4LOXL2LOX | |
| SCHEMBL31532578 | 0.67 | SMARCA2 (0.33) | ALDH1A1KDM4ESMARCA2SMARCA4ALPL | |
| SCHEMBL26739791 | 0.67 | SMARCA2 (0.41) | HSP90AA1HSP90AB1ALDH1A1KDM4ESMARCA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12391663-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS AG (CH) | 2025-08-19 | — | — | US | disclosed |
| US-12358906-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2025-07-15 | — | — | US | disclosed |
| CN-118666832-A | Urea compounds and compositions as SMARCA2/BRM atpase inhibitors | 诺华股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20240270738-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2024-08-15 | — | — | US | disclosed |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-08-08 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| CN-112585136-B | Urea compounds and compositions as SMARCA2/BRM atpase inhibitors | 诺华股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-11958846-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | NOVARTIS AG (CH) | 2024-04-16 | — | — | US | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2022133345-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20210323956-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| US-20210323956-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2021-10-21 | — | — | US | disclosed |
| EP-3837256-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | Novartis AG (CH) | 2021-06-23 | — | — | EP | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021069705-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS (CH) | 2021-04-15 | — | — | WO | disclosed |
| CN-112585136-A | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | 诺华股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2020227020-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| WO-2020035779-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035779-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | NOVARTIS AG (CH) | 2020-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11958846-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | SMARCC1, SMARCC2, SMARCA1 | CA2 3613/4885CHKA 1056/4885HSP90AA1 648/4885 |
| US-12391663-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CA2 462/4885CHKA 184/4885HSP90AA1 3750/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | CA2 462/4885CHKA 184/4885HSP90AA1 3750/4885 |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | CA2 1565/4885CHKA 1153/4885HSP90AA1 2410/4885 |
| US-20210323956-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | SMARCC1, SMARCC2, SMARCA1 | CA2 3613/4885CHKA 1056/4885HSP90AA1 648/4885 |
| US-12358906-B2 | Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors | SMARCC1, SMARCC2, SMARCA1 | CA2 2277/4885CHKA 1301/4885HSP90AA1 747/4885 |
| US-20240270738-A1 | UREA COMPOUNDS AND COMPOSITIONS AS SMARCA2/BRM ATPASE INHIBITORS | SMARCC1, SMARCC2, SMARCA1 | CA2 2272/4885CHKA 1282/4885HSP90AA1 720/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | CA2 462/4885CHKA 184/4885HSP90AA1 3750/4885 |
| US-20240261274-A1 | TREATMENT OF MYC-DRIVEN CANCERS WITH GSPT1 DEGRADERS | MYC, MYCBP, GSPT1 | CA2 4638/4885CHKA 3714/4885HSP90AA1 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.